Phase 2 introduces more variety and brings protein closer to target
ALL products and services offered are for laboratory and research activities exclusively
Our Score: 4/5 Before you sign up, heres how Ro performs across the most important categories
Retatrutide is a once-weekly subcutaneous peptide that simultaneously activates GIP, GLP-1, and glucagon receptors
doi: 10.3389/fphar.2025.1737199 Received 01 November 2025 Revised 21 December 2025 Accepted 29 December 2025 Published 15 January 2026 Volume 16 - 2025 Edited by Dawei Chen, University of Kiel, Germany Reviewed by Eveljn Scarian, University of Pavia, Italy Hong Cheng, Yangzhou University, China Updates Copyright 2026 Knudsen, Tadje, Coggins and Venketaraman